WANG, Jin Jean,YAKATAN, Gerald J.,LIN, Ting N.,GAO, Jing H.
申请号：
PE2019002140
公开号：
PE20200741A1
申请日:
2018.05.08
申请国别(地区):
PE
年份:
2020
代理人:
摘要：
It refers to a pharmacological synthesis, including: (a) two or more compounds, each of which is an independent (I) phosphatase inhibitor or antagonist of adenosine receptor, (II) calcium blocker, (III) promoter of H1 tissue receptor, 1. Agonists of H2 tissue receptor or H3 tissue receptor, or (IV) agonists of β - 2 tissue； and (b) acceptable drug precursors. This synthesis is carried out orally, intravenously, by parents or Topeka. He also mentioned a treatmentPrevention or improvement of cardiovascular disease, including the provision of an effective amount of cardiovascular treatment for people in need of treatmentSe refiere a una composicion farmaceutica que comprende: (a) dos o mas compuestos, en donde cada compuesto en la composicion farmaceutica es independientemente (i) un inhibidor de la fosfodiesterasa o un antagonista del receptor de adenosina, (ii) un bloqueador de los canales de calcio, (iii) un agonista del receptor de histamina H1, un agonista del receptor de histamina H2 o un antagonista del receptor de histamina H3, o (iv) agonista adrenoreceptor beta-2； y (b) un excipiente farmaceuticamente aceptable. Dicha composicion se administra por via oral, intravenosa, parenteral o topica. Tambien se refiere a un metodo para tratar, prevenir o mejorar una enfermedad cardiovascular que comprende administrar al sujeto que lo necesita una cantidad terapeuticamente efectiva de dicha composicion
